BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $55.00 at HC Wainwright

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective trimmed by HC Wainwright from $60.00 to $55.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

Several other research analysts have also weighed in on the stock. Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research note on Monday, November 3rd. Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Piper Sandler lowered their target price on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Truist Financial boosted their price target on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Finally, Leerink Partners downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Fifteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

BioMarin Pharmaceutical Stock Down 1.9%

NASDAQ BMRN opened at $61.44 on Wednesday. The business’s fifty day simple moving average is $58.72 and its 200-day simple moving average is $56.12. The company has a quick ratio of 3.10, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. The firm has a market cap of $11.80 billion, a PE ratio of 34.52, a P/E/G ratio of 0.68 and a beta of 0.26. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $73.51.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of BMRN. CIBC Private Wealth Group LLC raised its stake in BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of BioMarin Pharmaceutical by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after acquiring an additional 183 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 195 shares in the last quarter. Sittner & Nelson LLC raised its position in shares of BioMarin Pharmaceutical by 6.9% during the 2nd quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 200 shares in the last quarter. Finally, Grandfield & Dodd LLC lifted its stake in BioMarin Pharmaceutical by 1.2% during the third quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock worth $1,027,000 after purchasing an additional 217 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q4 earnings beat and record/strong revenue growth driven by Voxzogo, which supports near-term fundamentals. Q4 Highlights
• Positive Sentiment: Sanford C. Bernstein raised its price target to $94 and keeps an “outperform” rating, signaling bullish conviction from a major shop. Bernstein PT Raise
• Positive Sentiment: TD Cowen/Phil Nadeau maintained a Buy rating with a $120 price target, highlighting confidence in multi‑year growth and recent strategic moves. TD Cowen Note
• Neutral Sentiment: Bank of America reiterated a Buy but trimmed its target to $97, reflecting confidence in long-term upside while acknowledging nearer-term pressures. BofA Note
• Neutral Sentiment: Management will present at four investor conferences in March, which could provide additional investor visibility and updates on pipeline strategy. Investor Conferences
• Neutral Sentiment: Public short-interest data for February is effectively zero/unclear (likely reporting artifact) and does not appear to be a driver of today’s move.
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (its hemophilia gene therapy) from the market — a material strategic setback that raises questions about near- and medium-term revenue trajectory and risk profile. Roctavian Withdrawal
• Negative Sentiment: Several analysts trimmed targets or issued more cautious notes (Guggenheim lowered to $86, HC Wainwright cut to $55 and moved to Neutral), creating mixed sell-side signals and short-term pressure. Analyst Revisions

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.